Evogene Ltd. (NYSE: EVGN) reported Q2 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.66 million versus the consensus estimate of $4.4 million.

For earnings history and earnings-related data on Evogene Ltd. (EVGN) click here.